TRACON Pharmaceuticals (TCON)
(Delayed Data from NSDQ)
$1.85 USD
+0.07 (3.93%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $1.83 -0.02 (-1.08%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Tracon Pharmaceuticals (TCON) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$45.00 | $60.00 | $20.00 | 2,372.53% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Tracon Pharmaceuticals comes to $45.00. The forecasts range from a low of $20.00 to a high of $60.00. The average price target represents an increase of 2% from the last closing price of $1.82.
Analyst Price Targets (3 )
Broker Rating
Tracon Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/6/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Strong Buy |
9/8/2023 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
8/15/2023 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $45.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -1.20 |